Back to Search
Start Over
Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study
- Source :
- Blood Advances; October 2023, Vol. 7 Issue: 20 p6339-6350, 12p
- Publication Year :
- 2023
-
Abstract
- •Nanatinostat plus valganciclovir is a novel oral regimen for relapsed/refractory EBV+lymphoma that warrants further investigation.•Encouraging efficacy and safety were observed across a variety of EBV+lymphoma subtypes.
Details
- Language :
- English
- ISSN :
- 24739529 and 24739537
- Volume :
- 7
- Issue :
- 20
- Database :
- Supplemental Index
- Journal :
- Blood Advances
- Publication Type :
- Periodical
- Accession number :
- ejs63694798
- Full Text :
- https://doi.org/10.1182/bloodadvances.2023010330